Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma
- 11 October 2011
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 58 (3) , 327-333
Abstract
The similarities between human and canine osteosarcoma with regard to histology, biological behavior and molecular genetic alterations suggest that the dog provides a supplementary model for the development and preclinical testing of novel therapeutics. Counter intuitively, careful examination of the differences between OS in the two species may also be rewarding in terms of increasing our understanding of the pathogenesis of this cancer. This review will discuss the arguments in favor of the “dog model” and outline how the evaluation of treatment strategies in dogs has indicated avenues for improvement of protocols for human patients. Pediatr Blood Cancer 2012; 58: 327–333.Keywords
This publication has 80 references indexed in Scilit:
- Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing programPediatric Blood & Cancer, 2011
- Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcomaCancer, 2011
- Height at diagnosis and birth-weight as risk factors for osteosarcomaCancer Causes & Control, 2011
- Frontline treatment of localized osteosarcoma without methotrexateCancer, 2011
- Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation ProcessCancer Research, 2010
- Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix MetalloproteinasesCancer Research, 2010
- Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing programPediatric Blood & Cancer, 2010
- Aerosol Gemcitabine: Preclinical Safety and In Vivo Antitumor Activity in Osteosarcoma-Bearing DogsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumorsCancer, 2008
- Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak ActivationJournal of Biological Chemistry, 2007